Physician profile
Issa Lo
NPI 1013546100
$1,704.60
in general payments reported to CMS, 2019-2025
15 companies · $243 in 2025
The $243 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $343 · 2022: $84.04 · 2023: $553 · 2024: $482 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,277.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $311.30 | 2021 | |
| Dexcom, INC. | $212.04 | 2023-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Glaxosmithkline, LLC. | $151.66 | 2022-2023 | Arexvy |
| Biogen, INC. | $148.92 | 2023-2024 | |
| Abbvie INC. | $146.28 | 2023 | |
| Amgen INC. | $114.66 | 2024 | Repatha |
| Daiichi Sankyo INC. | $107.91 | 2025 | Injectafer |
| Phathom Pharmaceuticals, INC. | $97.69 | 2024 | Voquezna |
| Sumitomo Pharma America, INC. | $96.51 | 2023 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $95.40 | 2024 | |
| Axsome Therapeutics, INC. | $86.60 | 2024 | Sunosi |
| Amarin Pharma, INC. | $66.63 | 2023 | |
| Avanir Pharmaceuticals, INC. | $31.28 | 2021 | |
| Gilead Sciences, INC. | $19.93 | 2025 | Veklury |
| Janssen Pharmaceuticals, INC | $17.79 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Issa Lo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.